Figure 1
From: Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis
Receiver operator characteristic (ROC) curves for discrimination of pancreatic adenocarcinoma (PC) from disease controls (DCs) and healthy volunteers (HVs) in both the centre-1 and centre-2 cohorts. The protein panel derived from ten-fold cross-validation (solid line), CA19-9 (dashed line) and biomarker panel + CA19-9 (dotted line). (A) PC vs DC (centre-1): ROC AUC=0.90 for the biomarker panel, 0.87 for CA19-9 and 0.97 for the biomarker panel + CA19-9. (B) PC vs DC (centre-2): ROC AUC=0.88 for the biomarker panel, 0.75 for CA19-9 and 0.93 for the biomarker panel + CA19-9. (C) PC vs HV (centre-1): ROC AUC=0.90 for the biomarker panel, 0.91 for CA19-9 and 0.99 for the biomarker panel + CA19-9. (D) PC vs HV (centre-2): ROC AUC=0.90 for the biomarker panel, 0.81 for CA19-9 and 0.96 for the biomarker panel + CA19-9.
